anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent large-scale multiomics studies suggest that genetic factors influence the chemical individuality of donated blood. To examine this concept, we performed metabolomics analyses of 643 blood units from volunteers who donated units of packed red blood cells (RBCs) on 2 separate occasions. These analyses identified carnitine metabolism as the most reproducible pathway across multiple donations from the same donor. We also measured l-carnitine and acyl-carnitines in 13 091 packed RBC units from donors in the Recipient Epidemiology and Donor Evaluation study. Genome-wide association studies against 879 000 polymorphisms identified critical genetic factors contributing to interdonor heterogeneity in end-of-storage carnitine levels, including common nonsynonymous polymorphisms in genes encoding carnitine transporters (SLC22A16, SLC22A5, and SLC16A9); carnitine synthesis (FLVCR1 and MTDH) and metabolism (CPT1A, CPT2, CRAT, and ACSS2), and carnitine-dependent repair of lipids oxidized by ALOX5. Significant associations between genetic polymorphisms on SLC22 transporters and carnitine pools in stored RBCs were validated in 525 Diversity Outbred mice. Donors carrying 2 alleles of the rs12210538 SLC22A16 single-nucleotide polymorphism exhibited the lowest l-carnitine levels, significant elevations of in vitro hemolysis, and the highest degree of vesiculation, accompanied by increases in lipid peroxidation markers. Separation of RBCs by age, via in vivo biotinylation in mice, and Percoll density gradients of human RBCs, showed age-dependent depletions of l-carnitine and acyl-carnitine pools, accompanied by progressive failure of the reacylation process after chemically induced membrane lipid damage. Supplementation of stored murine RBCs with l-carnitine boosted posttransfusion recovery, suggesting this could represent a viable strategy to improve RBC storage quality.
For Phase 2, participants randomized into the sham group will have the opportunity to return after 2 months from completing Phase 1. They will receive the active treatment while being unblinded to their treatment condition. Following 10 active treatment sessions, word retrieval and other cognitive tasks will again be completed immediately following the last HD-tDCS session and then a 2-month follow-up.
Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Signs and Symptoms – Symptoms of toxicity are those of morphine and alcohol, such as nausea, vomiting, miosis, cool and clammy skin, respiratory and CNS depression, bradycardia, hypotension, and skeletal muscle flaccidity. Noncardiogenic pulmonary edema may develop after opioid overdose and monitoring of heart filling pressure may be helpful. Ethanol has been demonstrated to cause hypoglycemia in children or adults with limited glycogen stores. In severe overdosage, apnea, circulatory collapse, cardiac arrest, and death may occur.

  
Treatment – To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

  
Initial management of opioid overdose should emphasize establishment of a secure airway and support of ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, blood glucose, etc. Naloxone antagonizes most effects of opioids. Protect the airway as naloxone may induce vomiting. Since naloxone has a shorter duration of action than opioids, repeated doses may be needed. In patients who abuse opioids chronically, a withdrawal syndrome may be manifest on administration of naloxone. This may include yawning, tearing, restlessness, sweating, dilated pupils, piloerection, vomiting, diarrhea, and abdominal cramps. This syndrome usually abates quickly as the effect of naloxone dissipates.

  
Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Since opium tincture can delay gastric emptying, evacuation of the stomach may be beneficial. Safeguard the patient’s airway when employing gastric emptying or charcoal.

Monitor for and treat hypoglycemia.

The use of forced diuresis, peritoneal dialysis, hemodialysis or charcoal hemoperfusion has not been established to be beneficial.
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to the development of effective agents of vegetable origin used for treatment of herpetic viral infection. Invention proposes two variants of agent as 40% tincture and fatty-base ointment. The proposed agent gives rapid therapeutic effect in expressed sickness stage and, except for, prevents development of complications. EFFECT: enhanced effectiveness of agent. 3 cl, 3 ex
A system and methodology for the acquisition of medical data from multiple, at-home patient measurement devices transfers the data via telephone communications to a remotely accessed data management and display system such as a Web-based data management system. The measurement device, which supports two-way communications between the patient and the database system, is extensible to support multiple plug-in medical devices and devices for patient input or identification. Collection of data is mediated through an interface device that is connected via a digital link (serial, network, or digital RF link) to single or multiple patient measurement devices. This interface device is connected to a network via wide area network means including standard phone lines. In the preferred embodiment, data transfer is mediated through pervasive DTMF phone networks. Although DTMF is the preferred format, alternative analog or digital audio tone formats may be used.
The invention provides a preparation method of a traditional Chinese medicine for treating blood stasis stagnation type hypochondriac pain, and belongs to the technical field of preparation methods of traditional Chinese medicines. Currently, vitamin B1 is generally adopted to treat blood stasis stagnation type hypochondriac pain, and is low in toxicity, but shock is caused to some patients who are injected by vitamin B1. The preparation method is characterized by comprising the following steps of immersing the following 30 Chinese medicines in water, namely circium japonicum, camellia, common cephalanoplos herb, osbeckia chinensis, folium artemisiae argyi, cactus, hairyvein agrimony, rhizoma bletillae, stove, carbonized hair, rumex japonicus, marmor serpentinatum, radix boehmeriae, madder, salvia plebeian, hollyhock flower, eclipta, longstamen onion bulb, tangerine seed, tangerine peel, orange, buckeye, tobacco, citron, nutgrass galingale rhizome, mangnolia officinalis, lychee seed, lychee, costustoot and liquorice; and decocting with slow fire to obtain decoction, which is the traditional Chinese medicine for treating blood stasis stagnation type hypochondriac pain. The traditional Chinese medicine has the advantages of short course of treatment and high cure rate. Monarch, minister, assistant and guide medicines are compatible. Adverse reactions, allergy reactions and toxic reactions caused by Western medicaments sulfonamides and antibiotics can be avoided while the traditional Chinese medicine is administrated.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements, or the use of electrolyte-free dextrose solutions to which individualized electrolyte supplements may be added.

Potassium therapy should be guided primarily by serial electrocardiograms, especially in patients receiving digitalis. Serum potassium levels are not necessarily indicative of tissue potassium levels. Solutions containing potassium should be used with caution in the presence of cardiac disease, particularly in the presence of renal disease, and in such instances, cardiac monitoring is recommended.

Solutions containing dextrose should be used with caution in patients with overt or known subclinical diabetes mellitus, or carbohydrate intolerance for any reason.

If the administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.
Inclusion criteria were as follows: Patients older than 18 years, with a complete colonoscopy, for CRC screening or post-polypectomy surveillance or diagnostic assessment. Exclusion criteria precluded patients with previous colectomy or an abdominal surgery in the last 6 months, patients with polyposis syndromes or inflammatory bowel diseases and if they were unfit for polypectomy or the polyp specimen was not retrieved for histology.
PURPOSE:To provide a skin cosmetic compounded with an extract composed mainly of sugar and amino acid and obtained by the hydrolysis of YOKUININ (seed of Coix laryma-jobi), having excellent moisture-retainability, effective in preventing drying of the skin and hair and giving softness thereto and expected to have skin-beautifying effect. CONSTITUTION:YOKUININ is hydrolyzed to effect the hydrolysis of the constituent starches, proteins and fibers to sugars and amino acids and the constituent fats (fatty acid esters) to free fatty acids. The free fatty acid is separated as YOKUININ oil with trichlorotrifluoroethane and the remaining extract composed mainly of sugars and amino acids is compounded to a skin cosmetic. The above extract is excellent as a humectant and is effective in suppressing the formation of melanin pigment by its tyrosinase inhibiting action. A skin cosmetic having the above activities can be produced by this process. The YOKUININ oil obtained as a by-product is liquid oil having low viscosity, free from stickiness and capable of imparting gloss to the skin and hair. Accordingly, the oil can be used as a component of a cosmetic, etc.
DERMOTIC OIL (fluocinolone acetonide) 0.01% ear drops contains fluocinolone acetonide [(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16, 17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C24H30F2O6. It has the following structural formula:

Fluocinolone acetonide has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.

Each gram of DERMOTIC OIL contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil and fragrances.

DERMOTIC OIL is formulated with 48% refined peanut oil. The bulk refined peanut oil, used in DERMOTIC OIL is heated at 246°C (475°F) for at least 15 minutes. The refined peanut oil used in DERMOTIC OIL is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million (ppm).
DOSAGE MUST BE INDIVIDUALIZED. The initial dosage of doxazosin tablets in patients with hypertension and/or BPH is 1 mg given once daily in the a.m. or p.m. This starting dose is intended to minimize the frequency of postural hypotension and first dose syncope associated with doxazosin tablets. Postural effects are most likely to occur between 2 and 6 hours after a dose. Therefore, blood pressure measurements should be taken during this time period after the first dose and with each increase in dose. If doxazosin tablet administration is discontinued for several days, therapy should be restarted using the initial dosing regimen.

Concomitant administration of doxazosin tablets with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking doxazosin tablets.
The objectives of the present study were to evaluate the acute toxicity, gastroprotective, therapeutic, anti-inflammatory and anti H. pylori activities of T. vulgaris total plant extract against ethanol-induced gastric ulcers in Sprague Dawley rats. Animals were divided into five groups i.e G-1 (Normal Control), Group 2 (ulcer control) were administered orally with 0.5% Carboxymethylcellulose (CMC), Group 3 (omeprazole treated) was administered orally with 20 mg/kg of omeprazole and Groups 4 and 5 (Low dose and High dose of the extract) were administered orally with 250, and 500 mg/ kg of Thymus vulgaris extract, respectively. After 1 hour, the normal group was orally administered with 0.5% CMC (5 ml/kg), whereas absolute alcohol (5ml/ kg) was orally administered to the ulcer control group, omeprazole group, and experimental groups. Stomachs were examined macroscopically and microscopically. Grossly, rats pre-treated with T. vulgaris demonstrated significantly decreased ulcer area and an increase in mucus secretion and pH of gastric content compared with the ulcer control group. Microscopy of gastric mucosa in the ulcer control group showed severe damage to gastric mucosa with edema and leukocytes infiltration of the submucosal layer. However, rats pretreated with omeprazole or Thyme vulgaris exhibited a mild to moderate disruption of the surface epithelium and lower level of edema and leukocyte infiltration of the submucosal layer. The T. vulgaris extract caused up-regulation of Hsp70 protein, down-regulation of Bax protein, and intense periodic acid Schiff uptake of the glandular portion of the stomach. Gastric mucosal homogenate of rats pre-treated with T. vulgaris exhibited significantly increased superoxide dismutase (SOD) and catalase (CAT) activities while malondialdehyde (MDA) level was significantly decreased. Based on the results showed in this study, Thymus vulgaris extract can be proposed as the safe medicinal plants for use and it has considerable gastroprotective potential via stomach epithelium protection against gastric ulcers and stomach lesions.
PURPOSE:To provide excellent wear resistance, corrosion resistance and toughness to the titled alloy and to improve the castability thereof by incorporating specific amounts of Si, Mn, Cr, Mo, Hf and B into the Ni based alloy. CONSTITUTION:The compsn. of the Ni based cast alloy for dentistry consists of, by weight, 0.1-6% Si, 0.1-3% Mn, 20-37% Cr, 1-20% Mo, 0.005-6% Hf, 0.0001-0.5% B and the balance Ni with inevitable impurities. 0.1-10% W and one or more kinds among 0.1-12% Ti, Nb and Ta are furthermore incorporated into the alloy at need. The alloy is prepd. by using a conventional high-frequency melting furnace and is cast by using a sand mold, etc. Since said cast alloy has high strength, high hardness and high toughness equal to or above the conventional Ni-Cr based alloy and has excellent castability, the cast having a complicated shape can soundly be produced with a fine cast case.
The invention relates to registering changes in vascular tone during and after a functional load, and processing data using spectral analysis methods within the frequency ranges of endothelial (0.0095-0.02 Hz), neurogenic (0.02-0.05 Hz), and myogenic (0.05-0.14 Hz) regulation mechanisms. Furthermore, the temperature of an area of a patient's skin is continuously registered. During the first 1-2 minutes, the temperature of the examined skin surface is increased to 38-42° C., and the heating power is fixed. Temperature fluctuations are registered over the course of 10 minutes. The heater is shut-off. Over the course of 10 minutes following the shut-off and a decrease in temperature to 30-32° C., temperature fluctuations continue to be registered, and the obtained values are compared, with coefficients being calculated for the relative change in the amplitudes of the temperature fluctuations, which are then used for determining the existence of a disorder in a vascular tone regulation mechanism.
PURPOSE:To obtain the titled central muscle relaxant with low toxicity, containing a specific pyridine derivative or salt thereof, having central nervous muscle relaxing action, capable of remitting charley horse, etc., caused by sequelae of cerebral circulatory disorder, such as cerebral apoplexy without inducing sleepiness. CONSTITUTION:A central muscle relaxant containing a pyridine derivative expressed by the formula (R<1> is H, lower alkyl, OH, lower alkoxy, carboxy, etc.; R<2> is OH, lower alkoxy, amino, etc.) or a pharmacologically acceptable salt thereof. Picolinic acid, fusaric acid, quinolinic acid anhydride, lutidinic acid, etc., are preferably cited the compound expressed by the formula. The salt thereof is, e.g. sodium or potassium salt, which is a metal salt of a carboxylic acid. The compound expressed by the formula is rapidly absorbed by a method for oral or intraperitoneal administration to exhibit action thereof.
The control group is a waitlist control group. Participants in the control group complete a survey, wait for 2 to 3 weeks, then are eligible to sign up for the workshop. During the wait-list period they complete 2 surveys.
Group BK received esketamine infusion at a rate of 0.3 mg/kg/h during surgery. Patients were provided with patient-controlled intravenous analgesia (PCIA) containing esketamine (1.5 mg/kg), butorphanol (0.15 mg/kg), and azasetron (20 mg) in a total volume of 100 ml within 48 hours after surgery.
PURPOSE:The titled formulating ingredient, containing aldioxa and sucralfate at a weight ratio within a specific range, capable of suppressing the recrudescence and recurrence of the peptic ulcer, and useful for treating intractable ulcer. CONSTITUTION:A formulating ingredient for treating peptic ulcer containing aldioxa (chemical name: aluminum dihydroxyallantoinate) and sucralfate (chemical name: aluminum salt of sucrose sulfate) at 1:(2-20) weight ratio. The aldioxa has the main antiulcer activity of enhancing the defensive factor and further the inhibitory activity against the aggressive factor. The sucralfate has the antipepsin, antacid action and protecting action on the stomach membranes. The use of the antiulcer agents in the above-mentioned formulating proportion exhibits improved synergistic effects unfound even in an increased dose of the simple agent, and the treating period and the dose can be reduced. The resultant agent is particularly useful for cases requiring the transfer to operation, etc.
NEW MATERIAL:A compound shown by the formulaI(R is H, lower alkyl, or halogen) and its acid addition salt. EXAMPLE:3- 2- 4-(2-Methoxyphenyl)-1-piperazinyl ethyl -2,4(1H, 3H)quinazolinedione. USE:A hypotensor. Useful as a remedy for diseases of circulatory organs. Having strong hypotensive action and action on the reduction in heart rate. PROCESS:A compound shown by the formula II is reacted with trichloromethylchloroformate in the presence of a base such as sodium hydrogencarbonate, triethylamine, etc., or reacted with urea in dimethylformamide under heating to give a compound shown by the formulaI.
After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
OBJECTIVE: The comorbidity of binge eating and heavy drinking (BE + HD) is concerning due to high prevalence and associated consequences. Affective pathways may maintain BE + HD, yet more micro-level research is needed. This study used ecological momentary assessment (EMA) to examine between-person and day-level relationships between positive and negative affect and binge eating or heavy drinking episodes in BE + HD.
METHODS: Participants (N = 53) were adults with binge-spectrum eating disorders who completed between 7 and 14 days of EMA prior to a treatment for binge eating.
RESULTS: Anxiety was highest on days with both binge eating and heavy drinking, while excitement and confidence were highest on days with only heavy drinking episodes for BE + HD. Global negative affect was relatively stable surrounding binge eating episodes. Guilt significantly increased prior to binge eating, and sadness significantly decreased following binge eating. Global positive affect significantly decreased prior to and stopped decreasing following heavy drinking episodes.
DISCUSSION: Results support binge eating being negatively reinforced by specific aspects of negative affect, while heavy drinking may be positively reinforced by global positive affect for individuals with BE + HD. Clinicians should incorporate interventions that focus on specific negative affect dimensions and that promote alternative rewarding activities besides heavy drinking.
The purpose of the current study is to evaluate the effects on child and family development of early community services, including a brief nurse home visiting program. The proposed study will be conducted in partnership with the brief nurse home visiting program and Sinai Hospital, both located in Baltimore, MD. For the purposes of this study, Sinai Hospital will serve as the community/catchment area. Nurse home visitors enroll new mothers into the nurse home visiting program while they are still in the hospital/maternity ward. When the current study officially begins, nurse home visitors will recruit new mothers into the nurse home visiting program every other day only (on odd dates). Research staff will recruit all Baltimore City residents who give birth at Sinai Hospital, regardless of odd/even birth date, while they are still in the hospital/maternity ward.
PURPOSE: A method for treating cancer using enigma and mdm2 interaction and enigma expression is provided to induce apoptosis of cancer cells by suppressing enigma expression. CONSTITUTION: A mdm2(mouse double minute 2) has reduced stability by suppressing expression or activation of enigma. The activation of p53 is increased by suppressing expression or activation of enigma. The suppression of enigma expression is performed by an antisense oligonucleotide which complementarily binds to mRNA of enigma gene, siRNA, short hairpin RNA or RNAi. The siRNA has a base sequence of sequence number 2. A composition for anti-cancer contains an inhibitor of enigma expression or activation as an active ingredient.